News & Insights

Blumberg Capital portfolio news, startup growth resources and industry insights

Home > News & Insights > Dorian Therapeutics Appoints Jeff George to Board of Directors

Dorian Therapeutics Appoints Jeff George to Board of Directors

Share

Dorian Therapeutics, a biotechnology company that develops treatments for age-related diseases leveraging its proprietary senoblocker technology, today announced that Jeff George has been appointed to the company’s Board of Directors. Mr. George brings to the company a proven track record of leading significant global pharmaceutical companies, overseeing growth, and creating value in the pharmaceutical and healthcare industries.

“Dorian Therapeutics is rapidly scaling our R&D programs and organization as we look to partner with leading pharmaceutical and healthcare organizations to make our therapeutics widely accessible,” said Maddalena Adorno, Ph.D., Cofounder and CEO of Dorian Therapeutics. “Jeff George is an excellent addition to our board and brings a wealth of leadership, strategic, and operational experience, which will help us to accelerate our efforts to create value for patients, shareholders, and other stakeholders.”

Read more.

Related Articles